# Rules-Based Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rules-based-medicine

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.myriadrbm.com
- Total disclosed funding: $25M
- Latest round: Series A (Oct 25, 2007)
- Investors on record: 3

## About

Rules-Based Medicine Inc. is focused on biomarker technology, providing advanced assays and testing services for drug development and diagnostics across various therapeutic areas.Rules-Based Medicine Inc. specializes in biomarker analysis and immunoassays, aiming to enhance research in therapeutic applications. Established in Austin, Texas, the company underwent a pivotal change when it was sold to Myriad Genetics in April 2011 for USD 80 mn. The total number of deals reported stands at 2. The latest funding round was a TRADE SALE involving Myriad Genetics, Inc., amounting to USD 80 mn, which reflects the full total raised by the company.MyriadRBM focuses on advancing research and development in biomarker technology and immunoassays. Their offerings include a variety of assays and testing services that facilitate the discovery and validation of biomarkers essential for therapeutic applications. The company serves a diverse clientele consisting of pharmaceutical firms, academic institutions, and clinical research organizations, all reliant on accurate biomarker data for drug development and diagnostics. MyriadRBM’s products are primarily utilized in research areas such as oncology, neurology, and infectious disease, aimed at improving patient management and treatment strategies. They operate in critical markets including North America, Europe, and parts of Asia, ensuring that their solutions reach a wide array of stakeholders in medical research and clinical trials.MyriadRBM generates revenue through contract research services, direct sales of testing kits, and collaborations with pharmaceutical companies. The company follows a transactional structure featuring B2B arrangements where clients utilize their biomarker assays during drug development. Pricing is determined by the complexity and specificity of the assays, with flagship products commanding premium pricing due to their advanced capabilities. Additionally, partnerships with research institutions involve collaborative studies where MyriadRBM contributes its technologies in exchange for funding or shared results, reinforcing its market position while fostering innovation.Looking ahead, MyriadRBM aims to introduce new products designed for enhanced biomarker analysis by 2012, further expanding their portfolio. The company plans to enter additional geographic markets, specifically targeting growth in Europe and parts of Asia by 2023. The recent funding from the TRADE SALE to Myriad Genetics will support these initiatives, allowing for increased investment in product development and market expansion efforts.

## Funding rounds

- Series A, Oct 25, 2007, $25M — Stephens Capital Partners, Cross Creek, Equity Group Investments

## Investors

- Stephens Capital Partners (https://capitalatlas.ai/funds/stephens-capital-partners) — Series A
- Cross Creek (https://capitalatlas.ai/funds/cross-creek) — Series A
- Equity Group Investments (https://capitalatlas.ai/funds/equity-group-investments) — Series A